Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). Humanetics began working with AFRRI to test an array of drug candidates using their highly developed capabilities. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from AFRRI to Humanetics. In the ensuing years, the Company has progressed this program into multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. Humanetics has two open INDs for BIO 300 and is currently in Phase II clinical trials.
The Company's scientific team has strong partnerships with private and public research institutions that have unique capabilities to test radiation modulators. Click here to learn more about our collaboration partners. Funding for our programs has come from private sources as well as multiple government appropriations, grants and contracts. Humanetics has received substantial funding from The National Cancer Institute (NCI), The National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), The National Space Biomedical Research Institute (NSBRI), the National Aeronautics and Space Administration (NASA) and the Department of Defense (DoD).